Free Trial
NASDAQ:CGON

CG Oncology Q1 2025 Earnings Report

CG Oncology logo
$24.40 +0.05 (+0.19%)
As of 11:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CG Oncology EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.36
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

CG Oncology Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
$0.53 million
Beat/Miss
Missed by -$480.00 thousand
YoY Revenue Growth
N/A

CG Oncology Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

CG Oncology's Q3 2025 earnings is scheduled for Thursday, August 14, 2025

CG Oncology Earnings Headlines

CG Oncology (CGON) to Release Quarterly Earnings on Thursday
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
CGON - CG Oncology Inc Trailing Returns - Morningstar
See More CG Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email.

About CG Oncology

CG Oncology (NASDAQ:CGON), an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

View CG Oncology Profile

More Earnings Resources from MarketBeat